DOCSLIB.ORG

BMS Scoops Cormorant in $520M Immuno-Oncology Deal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BMS Scoops Cormorant in $520M Immuno-Oncology Deal GSK Gets Digital In Respiratory Is Pharma Geared For Big Efficiency Stockwatch In the latest installment of our Pay-Offs? As Brexit-induced volatility continued executive profile series, GSK’s SVP Eric Driving operational efficiencies may to reverberate across the stock market, Dube explains his expectations for not seem exciting in an industry racing investment bank analysts started to GSK’s future working with technology towards cures for cancer but some data downgrade companies (p21) & digital partners (p3) reveals why drab may be fab (p19) 15 July 2016 No. 3811 Scripscripintelligence.com Pharma intelligence | informa “We believe combination therapy will be foundational to delivering the poten- tial for long-term survival for patients, and the opportunity to develop the HuMax-IL8 antibody program together with our broad immuno-oncology pipeline enables us to accelerate the next wave of potentially transformational immunotherapies,” said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. Based on the nature of the molecule and the research phase it is in, analysts at Biomedtracker estimate that HuMax- IL8 currently has a likelihood of approval rating of 6%. Interleukin-8 was first characterized in Maarten de Château, CEO of Cormorant 1987 as a monocyte-derived neutrophil Pharmaceuticals chemotactic factor belonging to the CXC Shutterstock: Cormorant Pharmaceuticals AB Pharmaceuticals Cormorant Shutterstock: chemokine family. It is released from a variety of cells upon stimulation with IL-1, LPS, tumor necrosis factor alpha, viruses BMS Scoops Cormorant In $520M and lectins, and binds to two distinct, G- protein-coupled receptors (GPCRs) CXCR1 and CXCR2. Immuno-Oncology Deal While a number of IL-8 focused mol- MIKE WARD [email protected] ecules have been developed as candidate treatments of inflammatory diseases, BMS Bristol-Myers Squibb Co. has bolstered its HuMax-IL8, which is currently in Phase I/II de- has interest in IL-8 because of the growing immuno-oncology ambitions by acquir- velopment as a cancer agent. BMS will take body of evidence – the number of papers ing IL-8 focused Cormorant Pharmaceu- over immediate control of the current trial. published annually linking IL-8 with cancer ticals AB, the 4-year old Swedish biotech. In its bid to maintain its leadership in has trebled since 2002 – that the mediator Cormorant’s shareholders are getting immuno-oncology, Bristol-Myers Squibb is upregulated in many different solid tu- $95M up front with the promise of a fur- has been actively looking to further mors and is involved in tumor suppression. ther $425M if milestones are achieved. expand and solidify its pipeline either IL-8 has been identified as an important through development of single agents growth factor for cancer stem cells (CSC) S pharma giant Bristol-Myers Squibb or more commonly in combination with in breast cancer. Tumor cells secrete IL-8 Co. continues to reinforce its bur- other agents and had already concluded when killed by chemotherapy. Binding of Ugeoning immuno-oncology fran- a number of deals. Evidence that IL-8 IL-8 to CXCR1 can then stimulate growth chise with the $520M acquisition of Cormo- might have a role in cancer stem cell ac- of cancer stem cells which are able to self- rant Pharmaceuticals AB, a private Swedish tivity and tumor immunosuppression at- renew and possess the ability to regener- biotech with just one interleukin-8 (IL-8)- tracted the attention from a number of ate all different cell types of the parental focused human antibody asset in the clinic, oncology companies in Cormorant. CONTINUED ON PAGE 7 BROUGHT TO YOU BY THE EDITORS OF PHARMASIA NEWS, START-UP AND SCRIP INTELLIGENCE IN THIS ISSUE Boehringer Ingelheim is 5 cutting 724 jobs in the US, including 49 at its stateside corporate HQ Medivation has rejected GSK and the NIAID have a second, $1bn higher entered into a partnership buyout offer from Sanofi 9 to develop a Zika vaccine 15 COVER / BMS Scoops Cormorant In $520M Immuno- from the editor Oncology Deal [email protected] 3 GSK Gets Digital In Respiratory Under Optimistic Leadership Of Eric Dube As of July 11, Scrip’s content has been expanded to in- clude all the in-depth news, analysis and business intel- 5 Medivation Rejects Sanofi’s Latest Bid, ligence on key issues impacting the biopharmaceutical But Enters Confidential Negotiations industry from our former sister publications PharmAsia News and Start-Up. 6 Eyes Turn To Caldicott Review As Big Data Hopes All the editors and reporters working on Scrip, PharmA- Hit By Care.Data Closure sia News and Start-Up will continue to provide the con- tent that you have come to rely on. Now, though, under 8 AstraZeneca And Genzyme Breach Industry Code the expanded Scrip banner, there will be more available Of Practice for you in a single, integrated resource with improved 9 Boehringer Cuts 724 US Jobs To ‘Reinvent’ filtering options. Pharma Business For those readers joining us from PharmAsia News and Start-Up, the change also brings a new, responsive plat- 10 Business Bulletin form with simplified navigation and search tools and more customization options. Existing Scrip users will also 11 First European Cell Therapy Is Commercial Flop see some changes to the platform we moved to earlier this 12 Medidata advertorial year, and further improvements are planned later in 2016. For more information on the changes along with tips 13 Medidata advertorial on accessing your subscription, see https://pharmain- telligence.informa.com/less-is-more/. 14 R&D Bites We welcome your questions and comments. To dis- 15 GSK/NIH ‘SAM’ Strategy May Reap Benefits cuss matters related to your subscription or product ac- Beyond Zika cess, contact Customer Care at mailto: clientservices@ pharmamedtechbi.com. 15 Sanofi Teams With US Military On Zika, To discuss the editorial content of Scrip, reach out to But Not For The Profits me at [email protected]. 16 Tentative-Style Approvals Coming For US Biosimilars? 17 Policy & Regulation Briefs 18 NICE In CDF Rethink Says OK To Bosulif For General exclusive online content NHS Use In CML 19 Expert View: Is Pharma Geared For Big Efficiency Bristol’s Oncology Strategy: Cover All The Bases To Pay-Offs? Keep The Lead http://bit.ly/29yx0LI 21 Stockwatch: What Glimmer Through Yonder Bristol stresses comprehensive approach to lung cancer – its Gloom Breaks? top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with 22 Pipeline Watch drugs that have a wide range of targets. 23 Appointments Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations. @scripnews /scripintelligence http://bit.ly/29yxfGK /scripintelligence /scripintelligence 2 | Scrip intelligence | 15 July 2016 © Informa UK Ltd 2016 HEADLINE NEWS GSK Gets Digital In Respiratory Under Optimistic Leadership Of Eric Dube LUCIE ELLIS lucie.ellis@informacom Eric Dube took over GlaxoSmithKline PLC’s global respiratory LE: What was your first ever job? franchise in 2015 after holding several positions across the com- ED: I took over my neighbourhood newspaper route when I was 10. pany in the last 15 years, including an important role in Japan From that point on I can’t remember not having a job. that taught him leadership skills and an all new business way of life. In the latest installment of our executive profile series, in LE: How did you get into the industry? which Scrip gets behind the C-suite curtain, GSK senior vice pres- ED: I was in grad school when I was first introduced to the phar- ident Dube explains his expectations for GSK’s future working maceutical industry. At the time I was studying to be a profes- with technology and digital partners, the most challenging part sor of social and developmental psychology. I have always been of running a global franchise and what has inspired him over the drawn to learning, teaching and making a positive impact on the years to remain within the pharmaceutical industry. world through better understanding of science. But l was asked by a friend to do some freelance writing about the industry and I really enjoyed the pace of this business. From that time I was LUCIE ELLIS: How have you risen to a leadership position within really hooked. the industry? ERIC DUBE: I have always been eager to learn and challenge my- LE: How has the industry changed since your first experience? self and I also try to take an optimistic view toward the business, ED: One of the things that struck me when I first joined the industry our industry and our people. Pharma was not my chosen career was the debate around “Will pharma become much more collab- path, I wanted to be a professor and was planning to be one af- orative?” When I first joined, the discussion was focused on whether ter graduate school, but I saw the opportunity within pharma to we should collaborate on the discovery and development side of make an impact not just on an organization but on society as a things – and obviously we are seeing more big pharma acquiring whole. Without having that purpose I probably would not have and collaborating now, whether it’s with academia or biopharma. chosen the types of challenging roles and positions I have done But in the last couple of years I have seen more collaboration on so far in my career. My optimistic view that there must always be the commercial side – around digital, data and analytics, not just something more we can do as an industry has encouraged me to co-promotion.
Load more

Recommended publications
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm Laura Runkel Associate Director, Autoimmune/ Inflammation, CNS, Ophthalmology
    Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm Laura Runkel Associate Director, Autoimmune/ Inflammation, CNS, Ophthalmology Introduction Rheumatoid arthritis (RA) is a chronic disease next-line biologics. More recently, in 2012, a new that causes progressive articular damage and oral therapy, Pfizer’s Janus protein kinase (JAK) results in a wide range of systemic symptoms 1/3 inhibitor Xeljanz, was approved, opening the due to the associated inflammation. Treatment door to a novel therapeutic approach. Despite paradigms are well established for RA. Methotrexate, the many approved RA therapeutics, at least one a conventional synthetic disease-modifying third of patients remain, or become, unresponsive antirheumatic drug (csDMARD), is the first-line to treatment2. Because of this continued unmet therapeutic in the US, Japan, and five major EU need, and the growing prevalence of RA in an aging markets (France, Germany, Italy, Spain, and the population, industry interest in RA drug development UK)1. Further lines of approved therapeutics are remains high. This analysis, using Trialtrove clinical prescribed to DMARD-resistant patients, with the data, explores the recent clinical landscape, with an anti-TNFs being the major class of biologics in eye towards highlighting programs seeking durable this space. Other approved biologics (Actemra, treatment paradigms, and assessing where the Orencia, and Rituxan) that target different immune market is heading. regulatory pathways are generally prescribed as 1. Datamonitor Healthcare’s Treatment: Rheumatoid Arthritis, February 2017. 2. Hyrich KL, Lunt M, et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    [Show full text]
  • Impact Education RA Symposium.Pdf
    Educational Objectives • Assess decision support tools to enhance medical and pharmacy benefit design decision-making for patients with RA • Interpret results of decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA • Employ specialty pharmacy and disease management services that can improve the quality of care for patients with RA • Provide accurate and appropriate counsel as part of the managed care treatment team Assessing the Clinical Benefits of Rheumatoid Arthritis Therapies in a Managed Care Setting Robin K. Dore, MD Clinical Professor UCLA David Geffen School of Medicine Los Angeles, CA Learning Objective • Review the clinical benefits of early and aggressive treatment of rheumatoid arthritis (RA) RA Treatment Challenges • Complex, multifactorial Progression of RA pathogenesis Disability • Fluctuating clinical course; Inflammation unpredictable prognosis Joint damage • Characterized by units) • Progressive joint destruction Severity (arbitrary • Loss of physical function 0 5 10 15 20 25 30 Years of disease • Poor quality of life • Inflammatory joint symptoms determine disability early in natural history of the disease • Joint destruction dominates disability late in disease Adapted from Kirwan JR. J Rheumatol. 2001;28:881-886. RA Therapeutic Objectives Prevention/ Sustained arrest of remission joint damage Remission Prevention/ Prevention of reversal of systemic disability comorbidities Smolen JS, et al. Ann Rheum Dis. 2010;69:631-637. RA Treatment Strategy Early and Treat-to-Target Achieve Tight Intensive Achieve remission with Control Treatment minimal/no signs or Maintain remission or a Attenuate inflammation symptoms of active low level of disease quickly inflammation activity over time Smolen JS, et al. Ann Rheum Dis.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab Evidence Summary Beneficial for peripheral inflammatory conditions driven by IL-6 mediated pathology, but not well-suited for CNS compartmentalized inflammation, and suppress the immune system’s ability to fight pathogens. Neuroprotective Benefit: Can only reduce IL-6 mediated inflammation in the CNS if the BBB is disrupted. Effects of IL-6 in CNS are context dependent, so blocking IL-6 could improve or impair cognition in different patient populations. Aging and related health concerns: Mixed effects on cardiovascular health by raising LDL-c, while reducing Lp(a) and improving the function of HDL-c. May protect against IL-6 mediated heart damage, but have no clear benefit in cancer. Safety: Suppress immune system and pose risks for undetected infections that can become serious. Reduce
    [Show full text]
  • WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/16 (2006.01) A61K 39/395 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 39/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US20 16/042074 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 13 July 2016 (13.07.2016) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/192,269 14 July 2015 (14.07.2015) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/197,966 28 July 2015 (28.07.2015) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/277,201 11 January 2016 ( 11.01.2016) u s LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: IMMUNEXT, INC.
    [Show full text]
  • Table of Contents Protocol Amendment Summary of Changes
    Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Clinical Trial Protocol Clinical Trial Protocol Number MS200527-0060 Title A Phase IIb, Randomized, Double-blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate Phase IIb IND Number CCI EudraCT Number 2017-000384-32 Coordinating Investigator PPD Sponsor For all countries except the USA and Japan: Merck KGaA, Frankfurter Str. 250 64293 Darmstadt, Germany For Japan only: Merck Serono Co., Ltd. (Affiliate of Merck KGaA, Darmstadt, Germany) Arco Tower, 1-8-1 Shimomeguro Meguro-ku, Tokyo 153-8926, Japan And For the USA EMD Serono Research & Development Institute, Inc. 45A Middlesex Turnpike Billerica, MA 01821 USA Medical Responsible: PPD EMD Serono Research & Development Institute 45A Middlesex Turnpike, Billerica, MA 01821, USA Telephone: PPD 'RFXPHQW1RCCI 1/130 2EMHFW1RCCI Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Clinical Trial Protocol Version 12 July 2018/Version 3.0 (Amendment 4) Replaces Version 13 December 2017/Version 2.0 'RFXPHQW1RCCI 2/130 2EMHFW1RCCI Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Protocol Amendment Summary of Changes Protocol History Version Number Type Version Date 1.0 Original Protocol 11 May 2017 1.1 Amendment specific for US 03 July 2017 2.0 Global Amendment 13 December 2017 2.1 Amendment specific for US 16 November 2017 3.0 Global Amendment 12 July 2018 Protocol Version [3.0] (12-July-2018) This amendment is nonsubstantial based on the criteria in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study.
    [Show full text]
  • A61K9/51 (2006.01) — with International Search Report (Art
    ) ( 2 (51) International Patent Classification: Published: A61K9/51 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 19/033 875 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: 24 May 2019 (24.05.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/676,169 24 May 2018 (24.05.2018) US (71) Applicant: ELEKTROFI, INC. [US/US]; 75 Kneeland Street, 14th Floor, Boston, MA 021 11 (US). (72) Inventors: COFFMAN, Chase; 86 Worcester Street, Unit 3, Boston, MA 021 18 (US). CHARLES, Lyndon; 600 Main St Apt 3, Medford, MA 02155 (US). BROWN, Paul; 156 W 6th St, Unit 2, Boston, MA 02127 (US). DADON, Daniel, Benjamin; 2 Garden Court, Apt. 1, Cambridge, MA 02138 (US). LIU, Lisa; 111 Bartlett Street, Apt 2, Somerville, MA 02145 (US). SHADBAR, Sadiqua; 1307 Commonwealth Avenue, Apt 9, Allston, MA 02135 (US). SUDRIK, Chaitanya; 7 1 Elm Street, Apartment #2, Cam¬ bridge, MA 02139 (US). (74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Journal for Immunotherapy of Cancer (JITC) Preprint
    Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint is the author/funder, who has granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission. Until the paper has been able to undergo proper copyediting, typesetting, and author proofing, readers should be aware that the specific preprint information below may contain errors and has not been finalized by authors. The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin 6 Signaling in COVID-19 – related Systemic Inflammatory Response Fernanda I. Arnaldez, Steven J. O’Day, Charles G. Drake, Bernard A. Fox, Binqinq Fu, Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, Paolo A. Ascierto* Keywords: Immunomodulation, Inflammation mediators Fernanda I. Arnaldez, MD: Executive Medical Director, Clinical Development, MacroGenics, Inc., Maryland, USA Steven J. O’Day, MD: Executive Director, John Wayne Cancer Institute and Cancer Clinic Providence Saint John’s Health Center; Regional Director Research, Providence Los Angeles Metro Hospitals, Santa Monica, CA Charles G. Drake, MD, PhD: Director Genitourinary Oncology, Co-Director Immunotherapy, Associate Director for Clinical Research Herbert Irving Cancer Center, NYP/Columbia University Medical Center, New York, USA Bernard A. Fox, PhD: Harder Family Chair for Cancer Research, Earle A. Chiles Research Institute, Providence Cancer Institute, Oregon, USA Binqing Fu, PhD: Professor, School of Life Sciences, University of Science & Technology of China, Hefei City, China Walter J. Urba, MD, PhD: Director, Cancer Research, Earle A. Chiles Research Institute, Providence Cancer Institute, Oregon, USA Vincenzo Montesarchio: Director of Oncology Unit, A.O.R.N.
    [Show full text]
  • Statistical Analysis Plan
    Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 14 October 2019 / Version 2.0 Integrated Analysis Plan Clinical Trial Protocol MS200527-0060 Identification No. Title: A Phase IIb, Randomized, Double-blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate Trial Phase IIb Investigational Medicinal Evobrutinib Product(s) Clinical Trial Protocol 12 July 2018/Version 3.0 Version 16 November 2017/Version 2.1 (for US only) Coordinating Author Integrated Analysis Plan PPD , Merck KGaA / EMD Serono Research & Development Authors Institute, Inc. Function Author(s) / Data Analyst(s) PPD PPD PPD PPD PPD , EMD Serono PPD Research & Development Institute, Inc. Integrated Analysis Plan 14 October 2019 / Version 2.0 Date and Version 'RFXPHQW1RCCI 1/130 2EMHFW1RCCI Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 14 October 2019 / Version 2.0 Integrated Analysis Plan Merck KGaA / EMD Serono Research & Development Institute, Reviewers Inc. Reviewers: Function Name PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD Reviewers: Function Name PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD PPD This document is the property of Merck KGaA, Darmstadt, Germany, or one of its affiliated companies. It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany or its affiliate. Copyright © 2019 by Merck KGaA, Darmstadt, Germany or its affiliate.
    [Show full text]